EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Viela Bio's enterprise value is $2,545.22 Mil.
Viela Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2020 was $-151.43 Mil. Therefore, Viela Bio's EV-to-EBITDA for today is -16.81.
The historical rank and industry rank for Viela Bio's EV-to-EBITDA or its related term are showing as below:
VIE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.94 Med: -12.36 Max: -8.22
Current: -16.81
During the past 3 years, the highest EV-to-EBITDA of Viela Bio was -8.22. The lowest was -24.94. And the median was -12.36.
VIE's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.55
vs VIE: -16.81
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-05), Viela Bio's stock price is $53.01.
Viela Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was $-2.830. Therefore, Viela Bio's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Viela Bio EV-to-EBITDA Historical Data
The historical data trend for Viela Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Viela Bio's EV-to-EBITDA
For the Biotechnology subindustry, Viela Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viela Bio's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viela Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Viela Bio's EV-to-EBITDA falls into.
Viela Bio EV-to-EBITDA Calculation
Viela Bio's EV-to-EBITDA for today is calculated as:
Viela Bio's current Enterprise Value is $2,545.22 Mil.
Viela Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-151.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viela Bio (NAS:VIE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Viela Bio's share price for today is $53.01.
Viela Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.830.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Viela Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VIE has been successfully added to your 